PDZ and LIM Domain 2 (Mystique) Proteins (PDLIM2)

Mouse (Murine) PDZ and LIM Domain 2 (Mystique) (PDLIM2) interaction partners

1. Klotho (show KL Proteins) can modulate inflammation via PDLIM2/NF-kappaB (show NFKB1 Proteins) p65 (show NFkBP65 Proteins) pathway in cyclosporine A-induced nephropathy.

2. Deficiency in PDLIM2 resulted in the accumulation of STAT3 (show STAT3 Proteins) in the nucleus, enhanced the extent of TH17 cell differentiation, and exacerbated granuloma formation.

3. Pdlim2 is a novel actin-regulating protein of podocyte foot processes that may have a role in the pathogenesis of glomerular diseases.

4. PDLIM2 expression was sufficient to suppress in vitro anchorage-independent growth and in vivo tumor formation of colon cancer. PDLIM2 repression involves promoter methylation.

5. Knockdown of Mystique 2 with small interfering RNA abrogated both adhesion and migration in MCF10A and MCF-7 cells

6. SLIM is a novel ubiquitin E3 ligase whose targets include STAT (show STAT1 Proteins) proteins.

7. PDLIM2 deficiency resulted in larger amounts of nuclear p65 (show NFkBP65 Proteins), defective p65 (show NFkBP65 Proteins) ubiquitination and augmented production of proinflammatory cytokines in response to innate stimuli

8. Stat-interacting LIM protein as the critical Stat (show STAT1 Proteins) ubiquitin E3 ligase involved in osteopontin (show SPP1 Proteins) regulation of Stat1 (show STAT1 Proteins).

9. Suppression of PDLIM2 expression resulted in decreased cell adhesion, increased NF-kappaB (show NFKB1 Proteins) transcription reporter activity, and increased LPS (show TLR4 Proteins)-induced TNF-alpha (show TNF Proteins) production.

Human PDZ and LIM Domain 2 (Mystique) (PDLIM2) interaction partners

1. Data indicate that OR3A4 upregulation contributes to metastasis and tumorigenesis in gastric cancer by regulating the activation of PDLIM2, MACC1 (show MACC1 Proteins), NTN4, and GNB2L1 (show GNB2L1 Proteins).

2. We conclude that inactivation of PDLIM2 is a recurrent finding in cHL (show CHRDL1 Proteins) and ALCL, promotes activation of inflammatory signaling pathways and thereby contributes to their pathogenesis

3. Data show that shRNA mediated knockdown of PDZ and LIM domain protein 2 (PDLIM2) in both primary meningioma and schwannoma leads to significant reductions in cellular proliferation.

4. PDLIM2 is epigenetically repressed in ovarian cancer development and inhibition of PDLIM2 promoted ovarian cancer growth both in vivo and in vitro via NOS2-derived nitric oxide signaling, leading to recruitment of M2 type macrophages.

5. The suppression of PDLIM2 expression significantly reduced cell proliferation, cell growth and neoplasm invasiveness in prostate cancer cells.

6. epigenetic repression of PDLIM2 can be reversed by 5-aza-2-deoxycytidine and vitamin D to suppress KSHV-associated cancer cell growth

7. PDLIM2 expression is essential for feedback regulation of the beta1-integrin-RhoA (show RHOA Proteins) signalling axis and integration of cellular microenvironment signals with gene expression to control the polarity of breast epithelial acini structures.

8. PDLIM2 integrates cytoskeleton signaling with gene expression in epithelial differentiation by controlling the stability of key transcription factors and COP9 (show COPS8 Proteins) signalosome activity.

9. PDLIM2 was a direct target gene of 1,25(OH)2D3

10. Pdlim2 is a novel actin-regulating protein of podocyte foot processes that may have a role in the pathogenesis of glomerular diseases.